

Supplemental Digital Content 8

Table. Visual Function Outcome Measures at Baseline and Change From Baseline at Month 12 (ITT Population)

Visual Function	Mean (SD) Values at Baseline and Mean (SD) Change From Baseline Values at Month 12					
	Brimo DDS 132 µg Study Eye	Brimo DDS 132 µg Fellow Eye	Brimo DDS 264 µg Study Eye	Brimo DDS 264 µg Fellow Eye	Sham Study Eye	Sham Fellow Eye
BCVA, letters*						
Baseline	52.1 (13.9)	46.2 (20.2)	54.8 (12.9)	57.0 (17.4)	53.7 (10.7)	53.4 (20.9)
Month 12	+0.5 (10.7) n=49	-2.9 (13.1) n=49	-1.9 (11.5) n=41	-2.3 (10.0) n=41	-0.6 (11.8) n=23	+1.7 (10.9) n=23
Contrast sensitivity, letters†						
Baseline	22.1 (5.8)	20.0 (7.2)	23.7 (5.6)	23.9 (6.1)	21.7 (7.6)	20.9 (8.3)
Month 12	+2.2 (5.4) n=41	+1.6 (5.2) n=41	+0.7 (4.1) n=34	-0.3 (4.8) n=34	+3.9 (7.4) n=22	+2.0 (8.3) n=22
Reading speed, seconds†						
Baseline	9.6 (9.2)	9.4 (9.9) n=48	10.2 (8.5)	14.1 (11.2)	8.7 (6.8)	12.3 (10.7)
Month 12	+1.0 (5.8) n=41	-0.3 (7.9) n=41	+0.7 (4.2) n=34	-0.3 (7.5) n=34	+2.7 (4.2) n=22	+1.1 (5.1) n=22

BCVA, best-corrected visual acuity; Brimo DDS, brimonidine drug delivery system; ITT, intent-to-treat.

*Missing values during follow-up were imputed with the last-observation-carried-forward method.

†Analysis used observed values with no imputation for missing values.